Daiichi Sankyo has taken a significant step toward expanding treatment options in Japan by submitting regulatory approval for Enhertu, an advanced cancer-fighting drug designed to prevent recurrence in early-stage breast cancer patients, as is reported by PharmaBiz.com. The submission targets a particularly challenging patient population: those whose tumors still contain cancer cells after intensive chemotherapy prior to surgery.
Addressing a Critical Treatment Gap
Approximately half of patients undergoing pre-surgical chemotherapy for HER2 positive breast cancer fail to achieve complete tumor elimination before their operations. These patients face dramatically elevated risk of disease recurrence, yet current standard treatments have proven inadequate at preventing progression. Once cancer spreads to distant sites, survival rates plummet from nearly 90% to approximately 30%, making prevention of recurrence a clinical priority.
The Japanese submission represents an opportunity to fill this therapeutic void. Breast cancer remains the most commonly diagnosed malignancy among Japanese women, with roughly 92,000 annual cases and 17,600 deaths in 2022. Globally, the disease affects more than 2 million people yearly and claims over 665,000 lives.
The Drug and Its Mechanism
Enhertu is an antibody-drug conjugate, a sophisticated therapeutic design that combines a targeting antibody with cytotoxic cargo. The medication specifically recognizes HER2, a growth-promoting protein abnormally abundant on many breast cancer cells. Once attached to cancer cells, Enhertu delivers potent chemotherapy directly to tumors while minimizing exposure to healthy tissues.
The drug employs Daiichi Sankyo’s proprietary DXd technology platform, which uses tetrapeptide linkers to deliver topoisomerase I inhibitor payloads. This precision engineering allows for enhanced tumor-killing capability with potentially improved tolerability compared to conventional chemotherapy approaches.
Supporting Clinical Evidence
The regulatory submission draws strength from DESTINY-Breast05, a large international Phase 3 trial involving 1,635 patients across multiple continents. The study compared Enhertu to trastuzumab emtansine (T-DM1), the current standard of care in this setting. Results demonstrated that Enhertu significantly extended invasive disease-free survival, the time before cancer recurrence or death, compared to the established treatment.
These findings earned Enhertu breakthrough therapy designation from the U.S. FDA and prompted regulatory submissions in the European Union as well. The consistent positive results across different regulatory regions suggest robust therapeutic benefit in preventing post-operative breast cancer recurrence.
Expanding Treatment Arsenal
Enhertu already carries approvals in more than 90 countries for treating advanced HER2 positive breast cancer in patients whose disease has progressed despite prior anti-HER2 therapy. The drug has also demonstrated effectiveness against HER2 low breast cancer, certain lung cancers with HER2 mutations, and gastric cancers. Regulatory submissions pending in Japan include additional indications combining Enhertu with other agents and applications in other cancer types.
Future Implications
Daiichi Sankyo’s Japanese submission reflects broader momentum in precision oncology. By targeting specific molecular drivers of cancer growth while employing sophisticated drug delivery mechanisms, therapies like Enhertu represent a evolution beyond conventional chemotherapy. The company’s extensive clinical development program continues evaluating this technology across multiple cancer types and treatment combinations.
If approved by Japan’s Ministry of Health, Labour and Welfare, Enhertu could provide Japanese patients with residual early-stage HER2 positive breast cancer a powerful new option for preventing recurrence and improving long-term survival prospects.
